Victory Capital Management Inc. Decreases Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Victory Capital Management Inc. trimmed its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAXFree Report) by 9.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 300,269 shares of the biopharmaceutical company’s stock after selling 32,245 shares during the period. Victory Capital Management Inc.’s holdings in Dynavax Technologies were worth $4,435,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in DVAX. American Century Companies Inc. raised its holdings in Dynavax Technologies by 4.7% in the 1st quarter. American Century Companies Inc. now owns 86,892 shares of the biopharmaceutical company’s stock worth $942,000 after acquiring an additional 3,902 shares during the last quarter. HighTower Advisors LLC purchased a new position in Dynavax Technologies in the 1st quarter worth approximately $159,000. MetLife Investment Management LLC raised its holdings in Dynavax Technologies by 57.4% in the 1st quarter. MetLife Investment Management LLC now owns 57,543 shares of the biopharmaceutical company’s stock worth $624,000 after acquiring an additional 20,984 shares during the last quarter. Allianz Asset Management GmbH raised its holdings in Dynavax Technologies by 16.8% in the 1st quarter. Allianz Asset Management GmbH now owns 59,070 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 8,500 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Dynavax Technologies by 25.6% in the 1st quarter. Mackenzie Financial Corp now owns 16,190 shares of the biopharmaceutical company’s stock worth $175,000 after acquiring an additional 3,300 shares during the last quarter. 99.13% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO David F. Novack sold 9,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.45, for a total value of $130,050.00. Following the completion of the transaction, the chief operating officer now owns 3,187 shares of the company’s stock, valued at approximately $46,052.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, COO David F. Novack sold 9,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.45, for a total value of $130,050.00. Following the completion of the transaction, the chief operating officer now owns 3,187 shares of the company’s stock, valued at approximately $46,052.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO David F. Novack sold 20,000 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.56, for a total transaction of $271,200.00. Following the completion of the transaction, the chief operating officer now directly owns 3,187 shares of the company’s stock, valued at approximately $43,215.72. The disclosure for this sale can be found here. Insiders sold a total of 30,500 shares of company stock valued at $423,750 in the last 90 days. Company insiders own 9.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DVAX. HC Wainwright boosted their target price on shares of Dynavax Technologies from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. JMP Securities boosted their price objective on shares of Dynavax Technologies from $25.00 to $27.00 and gave the company a “market outperform” rating in a research report on Friday, November 3rd. Finally, The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a research report on Thursday, February 1st. They set a “neutral” rating and a $20.00 price objective for the company.

View Our Latest Stock Analysis on DVAX

Dynavax Technologies Trading Down 0.6 %

Shares of DVAX stock opened at $12.90 on Thursday. Dynavax Technologies Co. has a 1 year low of $9.42 and a 1 year high of $15.15. The firm has a fifty day moving average price of $13.73 and a 200-day moving average price of $13.98. The company has a debt-to-equity ratio of 0.37, a current ratio of 15.40 and a quick ratio of 14.49. The company has a market cap of $1.67 billion, a price-to-earnings ratio of 33.08 and a beta of 1.26.

Dynavax Technologies Profile

(Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Further Reading

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXFree Report).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.